Pharvaris NV (NAS:PHVS)
$ 19.84 1.01 (5.36%) Market Cap: 1.02 Bil Enterprise Value: 703.79 Mil PE Ratio: 0 PB Ratio: 3.10 GF Score: 40/100

Pharvaris BV at Life Sciences Partners BioCapital Europe Conference (Virtual) Transcript

Mar 11, 2021 / 01:50PM GMT
Release Date Price: $29.99 (+2.04%)
Unidentified Analyst

Joining us now is Berndt Modig, CEO of Pharvaris. Mr. Modig is a co-founder of the company and has served as Chief Executive Officer since inception. He is also a Director, and prior to co-founding the company, Mr. Modig served as Chief Financial Officer of Prosensa Holding, a biopharmaceutical company focused on novel RNA modulating treatment for rare diseases like Duchenne muscular dystrophy from March 2010 through its IPO on NASDAQ in 2013, and until its acquisition by BioMarin Pharmaceuticals in January 2015.

Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2 receptor antagonists to patients by targeting this clinically-proven therapeutic target with novel small molecules. The Pharvaris team is advancing new alternatives to injected therapies for all subtypes of HAE and other bradykinin mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.

And I'm looking forward to Berndt's presentation. The company has also quite recently IPO-ed on NASDAQ,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot